Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose...
Enregistré dans:
Auteurs principaux: | Maria Vinaixa, Miguel Angel Rodriguez, Sara Samino, Marta Díaz, Antoni Beltran, Roger Mallol, Cinta Bladé, Lourdes Ibañez, Xavier Correig, Oscar Yanes |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a609a2e2f41b4e308298f6adaac9d0a5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Comparison of Flutamide and Metformin in Overweight-Obese Women with Polycystic Ovary Syndrome Following a Hypocaloric Dieting
par: S Esmaeilzadeh, et autres
Publié: (2010) -
Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.
par: Vibe Skov, et autres
Publié: (2008) -
Brown Adipose Transplantation Improves Polycystic Ovary Syndrome-Involved Metabolome Remodeling
par: Lihua Yao, et autres
Publié: (2021) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
par: Holl, et autres
Publié: (2014) -
Engineering brain activity patterns by neuromodulator polytherapy for treatment of disorders
par: Mostafa Ghannad-Rezaie, et autres
Publié: (2019)